Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: Background/Objectives: To assess overall and type-specific HPV vaccine effectiveness in central and eastern Europe (CEE), the age-stratified prevalence of cervical HPV infection was determined among Slovenian women aged 20 to 64 attending a cervical cancer screening program 14 years after implementation of a national HPV vaccination program, which was then compared with 2009-2010 pre-vaccination data using the same methodological approach. Methods: Cervical samples of 4419 women were tested in 2023-2025 using the clinically validated Alinity m HR HPV Assay, and individual HPV types were determined by the Allplex HPV HR Detection assay. Results were compared with 2009-2010 pre-vaccination data generated using the same assay on an age-range matched cohort of women. Results: The overall prevalence of the 14 Alinity-targeted HPV types was 10.0% in 2023-2025 versus 13.3% in 2009-2010 (p < 0.001). HPV16 prevalence declined from 3.5% to 1.5% (p < 0.001), and HPV18 prevalence from 1.1% to 0.5% (p = 0.005). In women aged 20 to 24 with 40% uptake of quadrivalent HPV vaccine, overall HPV prevalence dropped from 25.3% to 12.8% (p < 0.001). No single case of HPV16/HPV18 infection was detected among vaccinated women. Conclusions: The first large-scale, systematic, and methodologically consistent study of HPV vaccine effectiveness in CEE showed a substantial reduction in high-risk HPV prevalence after implementation of the national program, with the greatest decline among women aged 20 to 24, who harbored the highest HPV burden in the pre-vaccination era. These locally acquired data will considerably inform public health strategies on cervical cancer elimination in CEE.
Ključne besede: HPV, Slovenia, central ane eastern Europe, cervical cancer, prevalence, screening, vaccination
Objavljeno v DiRROS: 20.04.2026; Ogledov: 185; Prenosov: 123
Celotno besedilo (1001,34 KB)
Gradivo ima več datotek! Več...

Povzetek: Background and aims: In contrast to extensively studied hypercholesterolemia, knowledge of hypocholesterolemia is limited. This study aims to assess the prevalence, clinical characteristics, and genetics of children and adolescents with hypocholesterolemia. Methods: This national prospective cross-sectional cohort study was part of Slovenia's universal opt-out cholesterol screening program. The first part assessed hypocholesterolemia prevalence among 3538 children aged 5 years, randomly selected at the mandatory check-up. The second part included analysis of demographic and clinical data and genetic testing of 71 individuals with suspected hypocholesterolemia (total cholesterol [TC] < 3.0 mmol/L [116.0 mg/dL]) referred to the Lipid Clinic of University Children's Hospital Ljubljana. Results: The prevalence of hypocholesterolemia among 3538 children was 2.66 % (95 % CI: 2.13-3.19 %). Among the 71 genetically tested individuals with suspected hypocholesterolemia, those with pathogenic variants had lower TC (2.58 ± 0.44 mmol/L vs. 2.85 ± 0.42 mmol/L [99.77 ± 17.02 mg/dL vs. 110.20 ± 16.24 mg/dL]; p = 0.037) and low-density lipoprotein cholesterol (1.00 ± 0.40 mmol/L vs. 1.33 ± 0.40 mmol/L [38.67 ± 15.47 mg/dL vs. 51.43 ± 15.47 mg/dL]; p = 0.014) compared to those without such variants. Genetic testing identified pathogenic alterations in 15 subjects, including 4 novel loss-of-function variants in the APOB gene. All but one subject were asymptomatic. Conclusions: This study provides new clinical and genetic insights into hypocholesterolemia. Asymptomatic patients with hypocholesterolemia may not require further evaluation, but additional research is needed to understand hypocholesterolemia better.
Ključne besede: APOB, children, hypocholesterolemia, next-generation sequencing, prevalence
Objavljeno v DiRROS: 09.04.2026; Ogledov: 218; Prenosov: 194
Celotno besedilo (1,96 MB)
Gradivo ima več datotek! Več...

Povzetek: Background Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID.
Ključne besede: HCV, hepatitis C, chronic hepatitis, prevalence, elimination, Europe
Objavljeno v DiRROS: 27.02.2026; Ogledov: 345; Prenosov: 239
Celotno besedilo (991,98 KB)
Gradivo ima več datotek! Več...

Povzetek: Research question (RQ): What is the prevalence of incontinent patients in acute hospital settings? How do staff choose incontinence devices for patient care? Purpose: The purpose of the study is to find out what proportion of incontinent patients are managed in acute hospital settings and to find out what incontinence devices are used by staff to care for incontinent patients and how. Based on the findings, we want to implement measures to improve the quality of care for patients with incontinence. Method: We used a descriptive method to review the literature, developed a questionnaire for data collection, trained staff on how to conduct the survey, and measured the point prevalence of incontinence using a cross-sectional survey. Results: Slightly more men (51.6%) than women (47.3%) were included in the survey, and for 1.1% of the patients, gender information was not available. Of the 1,277 patients included in the study, 750, or a good half (58.7%), were continent and did not use incontinence devices. A further 83, or 6.5%, were continent and used incontinence devices. 31.1% or 397 patients were incontinent and used incontinence devices, while 17 or 1.6% did not, despite being incontinent. For 2.3% of patients, no information was available. The point prevalence was 32.4%. Organisation: Good organisation is essential for good quality care for incontinent patients, so it is important to improve the quality of care for incontinent patients based on the findings. Society: Adequate patient awareness of incontinence is of paramount importance for the reduction and management of incontinence in the population. Originality: This is the first study in Slovenia to report the prevalence of incontinence in acute hospital settings. Limitations/follow-up research: The survey was conducted in a single tertiary care institution; we recommend that such a survey be conducted in the remaining hospitals in Slovenia.
Ključne besede: incontinence, urinary incontinence rate, incontinence dermatitis, incontinence devices, quality, management, dignity, prevalence, acute hospital management, nursing documentation
Objavljeno v DiRROS: 20.01.2026; Ogledov: 425; Prenosov: 232
Celotno besedilo (506,26 KB)
Gradivo ima več datotek! Več...

Povzetek: Introduction: Sarcopenia is a multifaceted condition affecting between 10 and 16% of the global population, and although multiple classification algorithms exist, no prevalence has been reported for a representative sample of the Slovenian population. Furthermore, multiple behavioural factors, such as malnutrition, physical inactivity, sedentary lifestyle and lower cognitive function, can contribute to the risk of sarcopenia. This study aims to: a) determine sarcopenia prevalence among Slovenian older adults according to different classification algorithms, b) compare the agreement among the algorithms and c) evaluate the relationship between proposed risk factors and sarcopenia. Methods: 654 participants (≥60 years, 30.4% males) have been classified into sarcopenia groups according to eight algorithms, and agreement (Fleiss K) between them was calculated. Additionally, age, sex, nutritional status, physical activity, sedentary levels and cognitive function were assessed as sarcopenia risk/protective factors. Results: The prevalence of sarcopenia according to EWGSOP2 was 4.1%, ranging from 2.1% to 15.3%, when classified by all eight algorithms. Overall agreement between algorithms was weak (K=.429; 95% CI .414 to .444) with 0.6% of participants classified as sarcopenic by all eight algorithms. Adequate nutrition and physical activity were identified as protective factors, while age, lower cognitive function and sedentary lifestyle were considered risk factors. Conclusion: Sarcopenia prevalence among the Slovenian general population was lower than in the global population. We can conclude that different sarcopenia algorithms lead to a different prevalence of sarcopenia. It is of great importance to be cautious when comparing prevalences among studies and to further validate the classification algorithms.
Ključne besede: sarcopenia, prevalence, epidemiology, classification algorithms, risk factors
Objavljeno v DiRROS: 03.03.2025; Ogledov: 976; Prenosov: 586
Celotno besedilo (294,19 KB)
Gradivo ima več datotek! Več...